Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamyd
about
Antibiotics for secondary prevention of coronary heart diseaseEffect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trialMacrolide antibiotics and the risk of cardiac arrhythmiasVascular smooth muscle cell apoptosis in atherosclerosis.Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus: chronic infections and coronary heart disease.Atherosclerosis, inflammation, and infection.Inflammation, infection and atherosclerosis: do antibacterials have a role in the therapy of coronary artery disease?Chlamydia pneumoniae in atherosclerosis.Background and current knowledge of Chlamydia pneumoniae and atherosclerosis.Antibiotics in the prevention and treatment of coronary heart disease.Inflammation, infection, or both in atherosclerosis: the ROXIS trial in perspective.Collaborative multidisciplinary workshop report: clinical antimicrobial trials for primary and secondary prevention of atherosclerotic cardiovascular disease.Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia.Inclusion fluorescent-antibody test as a screening assay for detection of antibodies to Chlamydia pneumoniae.Atherosclerosis: an infectious disease?Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in miceCell wall-deficient bacteria as a cause of infections: a review of the clinical significance.Emerging relations between infectious diseases and coronary artery disease and atherosclerosis.Weighing the evidence for infection as a risk factor for coronary heart disease.Microorganisms in the aetiology of atherosclerosis.Novel risk factors for stroke: homocysteine, inflammation, and infection.Should antibiotics now be part of routine treatment of coronary heart disease?Assessment of subclinical atherosclerosis and cardiovascular risk.Potential infectious etiologies of atherosclerosis: a multifactorial perspectiveChronic infections and atherosclerosis/thrombosis.Role of antibiotics for the prevention of cardiovascular disease.Effect of clarithromycin on inflammatory markers in patients with atherosclerosis.Inflammatory and thrombotic mechanisms in coronary atherosclerosisCardiac risks associated with antibiotics: azithromycin and levofloxacinAcute coronary syndrome and chronic infection in the Cork coronary care case-control study.Inflammation and atherosclerosis.Antibiotic trials for coronary heart disease.Absence of Bacteria on Coronary Angioplasty Balloons from Unselected Patients: Results with Use of a High Sensitivity Polymerase Chain Reaction Assay.Sophisticated tests for susceptibility to atherosclerosis: an added value for heart hospitals.Infectious agents are not necessary for murine atherogenesis.in silico analyses of metabolic pathway and protein interaction network for identification of next gen therapeutic targets in Chlamydophila pneumoniaeChlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis.Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J miceMicrobial risk factors of cardiovascular and cerebrovascular diseases: potential therapeutical optionsChlamydia pneumoniae is not detectable in subretinal neovascular membranes in the exudative stage of age-related macular degeneration.
P2860
Q24201388-7603EDFB-B885-49D0-B151-825F08A08ED5Q33752851-D5B68096-AE3C-4991-A5B8-71BFE6CAF103Q33772270-B20ED072-FC0A-4697-BCC4-8150AB854D0AQ33785809-7BD1F930-65E6-47F8-BF07-63BD68730080Q33821315-DEE16490-CCE4-49DF-8AC0-8F9F8090BBF9Q33843534-0ABD7D90-E4A9-4FB6-A9CD-C8BAE8A017E5Q33871329-E0EDAB93-25BA-4B15-8834-8AB314344D45Q33890410-CDD6249E-6F9B-4E51-9E00-56856D8C697FQ33935003-1A7A3AD9-0BBF-497C-BB5C-3D23FDA1F495Q33935098-F07A7187-42E3-497D-9D8A-9794B632C5CEQ33935103-556F5954-BEC4-40BE-BB7A-6D25B998925AQ33935109-CDDCC625-B21C-4FE8-818B-6DC812B91678Q33943151-27EE735B-2E1C-4F4F-B737-F3C38CABADB9Q33943276-87865A7C-AA44-4C1F-ACF9-B918FA2E1825Q33972834-204DC5A1-9268-4DB7-964F-DDCA8EF4B95CQ33979917-9493803A-A4AA-45F8-9251-5664E7F370C0Q33984369-F47D3B73-D0A8-4B34-BD3D-ADBE2BF46028Q33987842-BB584B65-13B4-48C8-B792-417197A9172AQ34011168-D6BEB42E-3A39-423E-8A9A-0B1D8AD6BB30Q34065709-6EF7AA65-8F00-4665-B66B-22F02695E44AQ34107356-1FA84686-7B89-491B-9465-691EF06DE670Q34160606-3219F0B0-A818-419B-BF48-75652693630EQ34397021-970DF137-482E-47E0-B5C9-601E9E2C6B0BQ34465370-D1144BB6-E1A2-4747-B2CB-12A64CB3FE62Q34514051-2B0B6DF3-6D80-4475-95DA-9605C023BE7EQ34874476-6C6320C7-84FD-402E-A3B2-8F78243E1968Q35140098-5C08103C-0B90-45E1-B44B-C98843A1ED66Q35201247-828CB087-0ADA-45E9-90BE-E80C031114ACQ35502601-55268D75-DD99-4E67-B938-677091F85229Q35583359-977CB816-CAE9-4E0F-907A-E7314FCA4EA9Q35692019-6CCB68ED-A1E0-40FF-9A72-C3610DC47683Q35733945-1BE8D4DB-D307-4B53-B085-5473AB985715Q35875899-C135C205-51CB-4DE8-8A99-7D273E5EBC59Q36091141-CC106B24-E30E-47CE-94D8-04DBD8F5E7A0Q36368432-42CDAFBE-FFB4-4CD8-A520-9B9C86594057Q37049216-A511F49B-D78B-4F7D-9408-2E62AF1F9DBEQ37346172-3766D5B4-2EF8-47A3-AB8F-CA9DC57B05B9Q37568474-2C04D9B9-7593-4D74-884A-47118EC56330Q37856198-DAA299BC-28E0-46B9-94CC-58ED67190BF7Q37862257-BAC6A54E-C0A3-41E8-8DA4-F4C2761C2997
P2860
Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamyd
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 1999
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Randomized secondary preventio ...... cardial Infection with Chlamyd
@en
Randomized secondary preventio ...... cardial Infection with Chlamyd
@nl
type
label
Randomized secondary preventio ...... cardial Infection with Chlamyd
@en
Randomized secondary preventio ...... cardial Infection with Chlamyd
@nl
prefLabel
Randomized secondary preventio ...... cardial Infection with Chlamyd
@en
Randomized secondary preventio ...... cardial Infection with Chlamyd
@nl
P2093
P1433
P1476
Randomized secondary preventio ...... cardial Infection with Chlamyd
@en
P2093
Anderson JL
Carlquist J
Muhlestein JB
P304
P356
10.1161/01.CIR.99.12.1540
P407
P577
1999-03-01T00:00:00Z